Published on 4 Apr 2024 on Simply Wall St. via Yahoo Finance
Analysts Expect Breakeven For AxoGen, Inc. (NASDAQ:AXGN) Before Long
AxoGen, Inc. (NASDAQ:AXGN) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. On 31 December 2023, the US$352m market-cap company posted a loss of US$22m for its most recent financial year. The most pressing concern for investors is AxoGen's path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
See our latest analysis for AxoGen